These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23729081)

  • 41. Cost analysis of dialysis treatments for end-stage renal disease (ESRD).
    Goeree R; Manalich J; Grootendorst P; Beecroft ML; Churchill DN
    Clin Invest Med; 1995 Dec; 18(6):455-64. PubMed ID: 8714789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Finances of the independent dialysis facility.
    DeOreo PB
    Blood Purif; 2007; 25(1):7-11. PubMed ID: 17170530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Competition in kidney dialysis.
    Regulation; 1981; 5(1):9-12. PubMed ID: 10250377
    [No Abstract]   [Full Text] [Related]  

  • 44. Palliative dialysis in end-stage renal disease.
    Trivedi DD
    Am J Hosp Palliat Care; 2011 Dec; 28(8):539-42. PubMed ID: 21398269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective.
    Cohen JT; Neumann PJ
    Am J Kidney Dis; 2007 Sep; 50(3):362-5. PubMed ID: 17720514
    [No Abstract]   [Full Text] [Related]  

  • 46. Medicare payment options for recombinant erythropoietin therapy.
    Sisk JE; Gianfrancesco FD; Coster JM
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):93-7. PubMed ID: 1928087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Home dialysis in the new USA bundled payment plan: implications and impact.
    Golper TA; Guest S; Glickman JD; Turk J; Pulliam JP
    Perit Dial Int; 2011; 31(1):12-6. PubMed ID: 21282384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Aug; 57(32):875-6. PubMed ID: 18701878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Case-mix adjustment for an expanded renal prospective payment system.
    Hirth RA; Turenne MN; Wheeler JR; Pozniak AS; Tedeschi P; Chuang CC; Pan Q; Slish K; Messana JM
    J Am Soc Nephrol; 2007 Sep; 18(9):2565-74. PubMed ID: 17675667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinic ownership steady, but payment reform will be a test of survival.
    Neumann ME
    Nephrol News Issues; 2009 Jul; 23(8):46-7. PubMed ID: 19662910
    [No Abstract]   [Full Text] [Related]  

  • 51. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective.
    Lazarus JM; Hakim RM
    Am J Kidney Dis; 2007 Sep; 50(3):366-70. PubMed ID: 17720515
    [No Abstract]   [Full Text] [Related]  

  • 52. Health care costs of peritoneal dialysis technique failure and dialysis modality switching.
    Chui BK; Manns B; Pannu N; Dong J; Wiebe N; Jindal K; Klarenbach SW
    Am J Kidney Dis; 2013 Jan; 61(1):104-11. PubMed ID: 22901772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Will payment and quality-driven reform improve outcomes?
    Neumann ME
    Nephrol News Issues; 2012 Oct; 26(11):12. PubMed ID: 23427715
    [No Abstract]   [Full Text] [Related]  

  • 54. Medicare program; end-stage renal disease quality incentive program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Jan; 76(3):627-46. PubMed ID: 21261127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ASN End-Stage Renal Disease Task Force: perspective on prospective payments for renal dialysis facilities.
    Sedor JR; Watnick S; Patel UD; Cheung A; Harmon W; Himmelfarb J; Hostetter TH; Inrig JK; Mehrotra R; Robinson E; Smedberg PC; Shaffer RN;
    J Am Soc Nephrol; 2010 Aug; 21(8):1235-7. PubMed ID: 20675502
    [No Abstract]   [Full Text] [Related]  

  • 56. L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they?
    Steinman TI; Nissenson AR; Glassock RJ; Dickmeyer J; Mattern WD; Parker TF; Hull AR
    Nephrol News Issues; 2003 Apr; 17(5):28-30, 32-4, 36 passim. PubMed ID: 12715624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Commentary: health care payment reform and academic medicine: threat or opportunity?
    Shomaker TS
    Acad Med; 2010 May; 85(5):756-8. PubMed ID: 20124876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving adequacy of hemodialysis in Northern California ESRD patients: a final project report. Provider Participants and Medical Review Board of the TransPacific Renal Network.
    Brown J; Josephson M
    Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S85-94. PubMed ID: 11053593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. And then there were--?
    Neumann ME
    Nephrol News Issues; 2011 Sep; 25(10):11. PubMed ID: 21998975
    [No Abstract]   [Full Text] [Related]  

  • 60. Dialysis facility ownership and epoetin dosing in hemodialysis patients: an overview.
    Weiner DE; Levey AS
    Am J Kidney Dis; 2007 Sep; 50(3):349-53. PubMed ID: 17720511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.